Metabolic fate of 1-hexylcarbamoyl-5-fluorouracil after oral administration in mice
- 1 January 1980
- journal article
- research article
- Published by Taylor & Francis in Xenobiotica
- Vol. 10 (11) , 847-854
- https://doi.org/10.3109/00498258009033815
Abstract
The metabolic fate of a new antitumor agent, 1-hexylcarbamoyl-5-fluoro[6-14C]uracil (14C-HCFU) was compared with that of 5-fluoro[6-14C]uracil (14C-FU) after oral administration to mice. 1-(5-Hydroxyhexylcarbamoyl)-5-fluorouracil and 1-(5-oxohexylcarbamoyl)-5-fluorouracil were found as major intermediate metabolites of 14C-HCFU and were produced by .omega.-1 oxidation. FU was detected in plasma 180 min after oral administration of 14C-HCFU; unchanged FU disappeared within 60 min after 14C-FU. 14C-HCFU and resulting FU were retained in tissues for a long period after oral administration; administered 14C-FU was rapidly degraded.This publication has 8 references indexed in Scilit:
- Distribution of 1-hexylcarbamoyl-5-fluorouracil and 5-fluorouracil by oral administration in mice.Journal of Pharmacobio-Dynamics, 1979
- Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil against L1210 leukemia.CHEMICAL & PHARMACEUTICAL BULLETIN, 1978
- Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in Lewis lung carcinoma and B16 melanoma.Journal of Pharmacobio-Dynamics, 1978
- Metabolic Fate of 1-Hexylcarbamoyl-5-fluorouracil in RatsXenobiotica, 1978
- 5-Fluorouracil Derivatives. I. The Synthesis of 1-Carbamoyl-5-fluorouracilsBulletin of the Chemical Society of Japan, 1977
- ANTITUMOR ACTIVITY OF 1-HEXYLCARBAMOYL-5-FLUOROURACIL IN A VARIETY OF EXPERIMENTAL-TUMORS1976
- Studies on fluorinated pyrimidines: VII—the degradative pathwayBiochemical Pharmacology, 1959